Literature DB >> 29339708

Simultaneous subacute thrombosis in two new-generation drug-eluting stents in different vessels.

Duygu Ersan Demirci1, Deniz Demirci, Şakir Arslan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29339708      PMCID: PMC5864798          DOI: 10.14744/AnatolJCardiol.2017.8092

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We report a rare case of simultaneous subacute thrombosis in 2 new-generation drug-eluting stents (DES) in different vessels after cessation of ticagrelor therapy for 3 days. A 66 year-old man was admitted to our emergency department complaining of acute, severe chest pain. He had hypertension and diabetes mellitus for 20 years, was a smoker, and had a history of stent implantation in the left anterior descending artery (LAD) 6 years ago. His electrocardiography results (ECG) revealed inferior ST elevation. An emergent catheterization was performed, revealing a totally occluded proximal right coronary artery (RCA) and a critical thrombotic lesion on the left circumflex artery (LCX). Angioplasty was performed and 2 everolimus-eluting stents (PROMUS Element, 2.5x16 mm and 2.5x20 mm; Boston Scientific Corp., Marlborough, MA, USA) were deployed in the proximal RCA and 1 everolimus-eluting stent (PROMUS Element, 3.0x24 mm) in the mid LCX. A final coronary angiography showed patency of the 2 vessels with Thrombolysis in Myocardial Infarction (TIMI) 3 flow after percutaneous coronary intervention (PCI). He was discharged on hospital day 3 with a recommended course of treatment of dual antiplatelet therapy (aspirin 100 mg daily and ticagrelor 90 mg twice daily). After 10 days, the patient was readmitted to the emergency department with severe chest pain. ECG revealed inferoposterior ST segment elevation. The patient indicated that he had stopped taking the ticagrelor therapy 3 days earlier because of hematuria. He was hemodynamicly stable and taken to the catheterization laboratory for primary PCI, which revealed totally occluded proximal RCA and mid LCX at the same time, the site of the stents. Successful primary PCI with angioplasty was performed for both vessels with transradial access and a final angiography revealed TIMI 3 flow distal to the coronary stents. After 4 days of observation, he was discharged with a strict recommendation to continue dual antiplatelet therapy for at least 1 year. Stent thrombosis (ST) is a challenging problem that can lead to serious clinical consequences. In addition to patient characteristics or procedure factors, inadequate dual antiplatelet therapy is the main cause (1). Simultaneous subacute thrombosis of 2 new-generation DESs in different vessels is rare and there is little in the literature discussing this condition. Most cases of ST in the literature occurred in a single coronary vessel, and there are still some rare cases reporting simultaneous ST in multiple coronary vessels for bare metal stents and first-generation DESs (2, 3). But there are few reports about the same condition for new-generation DESs (4, 5). In conclusion, simultaneous ST in different new-generation DESs in multiple coronary vessels was extremely rare, but still a possible complication of PCI. This case strongly suggests that it be ensured that patients are properly educated about the importance of drug use and the potential severe consequences of antiplatelet therapy cessation. Our case also demonstrates that the use of multiple stents, irrespective of stent type, in multiple coronary artery lesions should be undertaken with great attention, especially in high-risk patients, such as acute myocardial infarction.
  5 in total

1.  Simultaneous multivessel acute drug-eluting stent thrombosis.

Authors:  Joel A Garcia; Adam Hansgen; Ivan P Casserly
Journal:  Int J Cardiol       Date:  2006-10-19       Impact factor: 4.164

2.  Nightmare: Simultaneous Subacute Stent Thrombosis of Different New-Generation Drug-Eluting Stents in Multiple Coronary Arteries.

Authors:  Po-Chao Hsu; Chen-An Chiu; Ho-Ming Su; Tsung-Hsien Lin; Chih-Sheng Chu
Journal:  Acta Cardiol Sin       Date:  2015-03       Impact factor: 2.672

3.  Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment.

Authors:  Flavio Airoldi; Antonio Colombo; Nuccia Morici; Azeem Latib; John Cosgrave; Lutz Buellesfeld; Erminio Bonizzoni; Mauro Carlino; Ulrich Gerckens; Cosmo Godino; Gloria Melzi; Iassen Michev; Matteo Montorfano; Giuseppe Massimo Sangiorgi; Asif Qasim; Alaide Chieffo; Carlo Briguori; Eberhard Grube
Journal:  Circulation       Date:  2007-07-30       Impact factor: 29.690

4.  Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.

Authors:  Sung-Won Jang; Dong-Bin Kim; Bum-Jun Kwon; Dongil Shin; Sung-Ho Her; Chan-Seok Park; Hoon-Joon Park; Man-Won Park; Eun-Ju Cho; Tae-Ho Rho; Jae-Hyung Kim
Journal:  Int J Cardiol       Date:  2008-12-30       Impact factor: 4.164

5.  Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism.

Authors:  Ashwad Afzal; Bimal Patel; Neel Patel; Sudhakar Sattur; Vinod Patel
Journal:  Case Rep Med       Date:  2016-07-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.